Observational studyMedical science monitor : international medical journal of experimental and clinical research2021

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.

Anthony Matta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.